TrialBlood2006

IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.

Mojgan Ahmadzadeh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.